Genta Incorporated: Clinical Trials

31 trials sponsored by Genta Incorporated, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 completed, 12 unknown, 3 terminated, 2 withdrawn. 17 Phase 2, 11 Phase 1, 7 Phase 3, 1 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 217Unknown 9, Completed 5, Terminated 2, Withdrawn 1
Phase 111Completed 7, Unknown 4
Phase 37Completed 4, Terminated 1, Unknown 1, Withdrawn 1
Early Phase 11Terminated 1

Follow Genta Incorporated: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer
Tesetaxel, Capecitabine - Locally Advanced Non-resectable Breast Cancer, Metastatic Breast Cancer
Phase 2UnknownGenta Incorporated2132012-05-012012-06-01
Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer
Tesetaxel, Placebo, Capecitabine - Gastric Carcinoma
Phase 2UnknownGenta Incorporated5802012-04-012012-07-24
Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer
Tesetaxel-capecitabine-cisplatin - Gastric Carcinoma
Phase 1 / Phase 2UnknownGenta Incorporated632011-05-012012-03-13
Study of Tesetaxel in Japanese Patients With Solid Tumors
Tesetaxel - Advanced Solid Tumors
Phase 1UnknownGenta Incorporated122011-04-012012-03-13
A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors
Tesetaxel plus capecitabine - Solid Tumor
Phase 1UnknownGenta Incorporated92011-03-012012-07-24
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
Tesetaxel - Prostate Cancer
Phase 2UnknownGenta Incorporated572011-02-012012-07-24
Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma
Genasense, Paclitaxel, Carboplatin - Melanoma
Phase 2TerminatedM.D. Anderson Cancer Center72010-12-012016-02-11
Tesetaxel as First-line Therapy for Metastatic Breast Cancer
Tesetaxel once every 3 weeks, Tesetaxel once weekly - Breast Neoplasm
Phase 2UnknownGenta Incorporated812010-11-012012-07-24
Tesetaxel for Previously Treated Patients With Bladder Cancer
Tesetaxel - Carcinoma, Transitional Cell
Phase 2UnknownGenta Incorporated332010-09-012012-07-11
Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsules
Tesetaxel 10 mg with and then without food, Tesetaxel 10 mg without and then with food - Solid Tumors
Phase 1CompletedGenta Incorporated122010-06-012012-07-24
Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer
Tesetaxel - Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction
Phase 2UnknownGenta Incorporated272010-03-012012-03-15
Phase II Study of Tesetaxel in Metastatic Melanoma
Tesetaxel - Advanced Melanoma, Cancer
Phase 2CompletedM.D. Anderson Cancer Center172010-02-012018-07-17
Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH
Tesetaxel - Melanoma
Phase 2UnknownGenta Incorporated272010-02-012011-11-08
Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
oblimersen sodium, rituximab, cyclophosphamide - Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Early Phase 1TerminatedUniversity of Nebraska372008-07-232023-10-24
Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
RICE, GaRD Treatment - Diffuse Large B-cell Lymphoma
Phase 2WithdrawnLoyola University2008-07-012016-03-16
Trial of Dacarbazine With or Without Genasense in Advanced Melanoma
dacarbazine plus Genasense, dacarbazine plus placebo - Melanoma
Phase 3CompletedGenta Incorporated3002007-07-012011-11-07
Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors
Oblimersen (Genasense) - Solid Tumors
Phase 1CompletedGenta Incorporated252007-05-012012-04-06
Abraxane and Temodar Plus Genasense in Advanced Melanoma
Genasense® (oblimersen), Abraxane® (paclitaxel protein-bound particles for injectable suspension), Temodar® (temozolomide) - Melanoma
Phase 1UnknownGenta Incorporated282006-11-012011-11-07
This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)
Genasense® (, oblimersen sodium G3139) - Lymphocytic Leukemia
Phase 3WithdrawnGenta Incorporated2006-06-012008-02-11
Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function
Genasense (oblimersen, G3139) - Normal Renal Function, Mildly Impaired Renal Function
Phase 1CompletedGenta Incorporated232006-05-012012-03-13

Showing 20 of 31. Sign in to see all of them.

Conditions studied

Melanoma (6)  ·  Leukemia (4)  ·  Neoplasms (4)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (3)  ·  Breast Neoplasms (2)  ·  Bronchiolitis Obliterans Syndrome (2)  ·  Lymphoma, Large B-Cell, Diffuse (2)  ·  Stomach Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Transitional Cell (1)  ·  Leukemia, Lymphoid (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Lung Neoplasms (1)  ·  Lymphoma (1)  ·  Lymphoma, Non-Hodgkin (1)

Interventions

oblimersen (16)  ·  tesetaxel (12)  ·  Capecitabine (4)  ·  Dacarbazine (3)  ·  Cyclophosphamide (2)  ·  Albumin-Bound Paclitaxel (1)  ·  Biopsy (1)  ·  Carboplatin (1)  ·  Cisplatin (1)  ·  Cytogenetic Analysis (1)  ·  Dexamethasone (1)  ·  Docetaxel (1)  ·  Doxorubicin (1)  ·  Filgrastim (1)  ·  Food (1)

Countries

United States (26)  ·  Canada (2)  ·  Germany (2)  ·  Italy (2)  ·  South Korea (2)  ·  Australia (1)  ·  Austria (1)  ·  Czechia (1)  ·  France (1)  ·  Japan (1)  ·  Poland (1)  ·  Russia (1)  ·  Spain (1)  ·  Switzerland (1)  ·  Taiwan (1)

Top investigators

Stanley R. Frankel, MD (4)  ·  Andrew D Seidman, MD (2)  ·  Jaffer Ajani, MD (2)  ·  Agop Y Bedikian, MD (1)  ·  Agop Y. Bedikian, MD, BS (1)  ·  Anna C Pavlick, MD (1)  ·  Dean F Bajorin, MD (1)  ·  Deborah Braccia (1)  ·  Harry Alcorn, PharmD (1)  ·  Harry W Alcorn, PharmD (1)  ·  Julie M Vose, MD MBA (1)  ·  Lee S Schwartzberg, MD, FACP (1)  ·  Michael J Morris, MD (1)  ·  Sapna P. Patel, MD (1)  ·  Scott Smith, MD, PhD, FACP (1)

Results publications

PMID 16186597, PMID 16730060, PMID 17296974, PMID 19373653, PMID 19738118

NIH funding

P30CA036727 (1)